MINNEAPOLIS--(BUSINESS WIRE)--New clinical data on a range of innovative medical devices from Medtronic, Inc. (NYSE: MDT), to treat cardiac and vascular diseases – from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease – will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17–20.
“Medtronic has never been better positioned to offer such an extensive array of technologies to address the difficult challenges that clinicians face every day,” said Michael J. Coyle, executive vice president of Medtronic, Inc., and president of the Cardiac and Vascular Group at Medtronic. “EuroPCR presents an excellent opportunity to share some of the latest clinical evidence on these technologies, which will be discussed in scientific sessions and showcased at the highly interactive Medtronic booth.”
Sessions of interest from the “Coronary and structural heart disease” and “Endovascular” programmes are listed below, all in Central European Summer Time (CEST):
Tuesday 17 May
10:00–11:00 / Welcome and Live Demonstration from Frankfurt (Main Arena)
- 10:10–10:30 / ‘Renal denervation: a new treatment option in hypertension and beyond?’
12:00–14:25 / What’s new in endovascular interventions? Late breaking trials (Room Maillot)
- 12:15–12:23 / ‘DESERVE study: diffusion weighted - magnetic resonance imaging based evaluation of the effectiveness of endovascular clamping during carotid artery stenting with the Mo.Ma device. Results from a prospective, multicentre study’
- 12:43–12:51 / ‘MARIS - 1,000 patient superficial femoral artery registry’
- 12:57–13:05 / ‘Drug-eluting balloon for the treatment of femoro-popliteal arterial disease: mid-term results from a multicentre Italian registry’
14:00–15:30 / The role of the interventional cardiologist from the coronary to the renal arteries (Room 342AB)
16:30–18:00 / Quality of life and neurocognitive function after TAVI (Room 353)
- 17:02–17:11 / ‘Health-related quality-of-life shows sustained improvement with transcatheter aortic valve’
Wednesday 18 May
12:00–13:30 / Which DES for diabetics? (Room 242B)
- 12:19–12:28 / RESOLUTE Pooled Diabetics: ‘Treatment with the Resolute Zotarolimus-eluting stent in subjects with diabetes mellitus: pooled analysis from the Resolute clinical programme’
- 12:32–12:41 / ‘Clinical outcomes in diabetic and non diabetic patients treated with Endeavor Resolute Zotarolimus eluting-stent: a multicentre Italian observational study’
15:00–16:30 / Renal denervation therapy (Room 342AB)
Thursday 19 May
09:00–10:30 / Management of arterial access in TAVI (Room 341)
- 09:32–09:41 / ‘1-year results of the subclavian access for TAVI with the CoreValve bioprosthesis in 132 consecutive patients’
16:30–18:00 / Risk of stent thrombosis and new generation DES (Room 353)
- 17:41–17:50 / ‘Safety of dual antiplatelet therapy interruption after Resolute stent implantation: an Italian multicentre observational evaluation’
Friday 20 May
09:10–12:10 / Late-Breaking Registries and Trial Updates (Room 342AB)
- 09:10–09:20 / RESOLUTE Pooled Safety: ‘Pooled analysis of the Resolute programme clinical safety results’
- 12:00–12:08 / ‘A weighted meta-analysis of early and late clinical outcomes after CoreValve percutaneous aortic valve replacement in seven national registries’
The CoreValve System, IN.PACT DEB, Resolute DES and Symplicity Catheter System are all investigational devices in the United States, where their use is limited by U.S. law to clinical studies approved by the FDA.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.